Portugal - português - myHealthbox

bayer ag - dispersão em óleo (od) com 22 g/l de isoxadifeno-etilo e 44 g/l de tembotriona - safener + tricetona

Portugal - português - myHealthbox

bayer ag - suspensão concentrada (sc) com 345 g/l de tembotriona, 134 g/l de isoxadifeno-etilo e 68 g/l de tiencarbazona-metilo - safener + sulfonilamino-carbonil-triazolinona + tricetona

Portugal - português - myHealthbox

bayer ag - dispersão em óleo com 22,5 g/l de foramsulfurão e 22,5 g/l de isoxadifeno-etilo - oxazol-carboxilato + sulfonilureia

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

brainfarma indÚstria quÍmica e farmacÊutica s.a - nitrato de isoconazol - antimicotico

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunossupressores - consulte o documento de informações do produto.

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmológicos - redução da pressão intra-ocular (pio) em pacientes com glaucoma de ângulo aberto ou hipertensão ocular que são insuficientemente responsivos aos beta-bloqueadores tópicos ou análogos de prostaglandina.

União Europeia - português - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artrite, reumatóide - imunossupressores - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

fipronil 134.0 mg ; metopreno-s 120.0 mg - caninos (cães) com 10-20 kg

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

fipronil 402.0 mg ; metopreno-s 361.8 mg - caninos (cães) com mais de 40 kg

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

fipronil 268.0 mg ; metopreno-s 241.2 mg - caninos (cães) com peso entre 20 kg e 40 kg